Evolución de la función pulmonar en niños con fibrosis quística durante los primeros 3 años de vida

Balinotti, Juan E; Chang, Daniel V; Lubovich, Silvina; Rodríguez, Viviana; Zaragoza, Silvina; Escobar, Natalia; Kofman, Carlos; Pérez, Gabriela L; Ardiles, Victoria; Teper, Alejandro.
Arch. argent. pediatr ; 117(5): 323-329, oct. 2019. graf, tab
Artículo en Inglés, Español | LILACS, BINACIS | ID: biblio-1054959

Documentos relacionados

  1. Course of lung function in children with cystic fibrosis in their first 3 years of life.
  2. [Italian Cystic Fibrosis Registry (ICFR). Report 2021-2022].
  3. Abdominal Surgical Procedures in Adult Patients With Cystic Fibrosis: What Are the Risks?
  4. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
  5. [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
  6. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
  7. Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children's hospital. A case series.
  8. Digital technology for early identification of exacerbations in people with cystic fibrosis.
  9. Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.
  10. The First 4 Years - Outcome of Children Identified by Newborn Screening for CF in Germany.